





Supplemental Figure S1 : Utility of liver enzymes for distinguishing cancers with liver metastases from local cancers (left) and from metastatic cancer without involvement of the liver (right), using ROC curves. A. ALT. B. AST. C. Combined ALT/AST. D. Combined ALT/AST and hepatocyte cfDNA.


A




B




C ALT/AST liver mets / all cancer




ALT/AST liver mets / other mets



D Hepatocytes CfDNA/ALT/AST liver mets / all cancer




Hepatocytes CfDNA/ALT/AST liver mets / other mets




Supplemental Figure S2 : Methylation of tissue-specific markers described in this study, using CpG sites covered by the Illumina Infinium 450k BeadChip array. A. Neuron markers. B. Oligodendrocyte markers C. Astrocyte markers D. Hepatocyte markers


A




B



C




D




Supplemental Figure S3: Methylation levels of CpG sites in our liver and brain-specific markers, using WGBS. (A) Neuron markers. (B) Oligodendrocyte markers. (C) Astrocyte markers. (D) Liver markers

A




B



C

Astrocyte markers

**D**

Hepatocyte markers

